Skip to content
Disclosery

Octagon Capital Advisors LP

Follow

13F filer, CIK 1839435, NEW YORK, NY

Octagon Capital Advisors LP reported $903,605,540 across 29 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15. Its ten largest share positions make up 68.62% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001839435-26-000003

Period
2026-03-31
Reported value
$904M
Holdings
29
Top 10 weight
68.62%
New
8
Sold out
6

Largest buys vs the previous quarter

SecurityShares changeApprox. value
DFTXnew+2,440,000$46.1M
MIRMnew+338,900$31.3M
XENEnew+490,000$28.5M
TERNnew+530,000$27.9M
IRONnew+270,000$17.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
DNTHreduced-470,000-$39.4M
MIND MEDICINE MINDMED INCexited-2,230,000-$29.9M
CDTXexited-100,000-$22.1M
RAPTexited-574,000-$19.4M
TRVIreduced-1,330,000-$15.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001839435-26-000003, largest first. % of portfolio is the value over $903,605,540, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,746,667 shares; 2024Q4: 2,110,167 shares; 2025Q1: 2,341,667 shares; 2025Q2: 2,341,667 shares; 2025Q3: 2,416,667 shares; 2025Q4: 2,416,667 shares; 2026Q1: 1,946,667 shares 1,946,667$163M18.08%-470,000Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,305,000 shares; 2024Q4: 2,763,000 shares; 2025Q1: 2,763,000 shares; 2025Q2: 2,763,000 shares; 2025Q3: 2,874,111 shares; 2025Q4: 2,350,000 shares; 2026Q1: 2,350,000 shares 2,350,000$90.5M10.01%0Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,230,000 shares; 2025Q2: 1,267,000 shares; 2025Q3: 1,325,000 shares; 2025Q4: 756,000 shares; 2026Q1: 677,000 shares 677,000$75.4M8.34%-79,000Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,530,700 shares; 2026Q1: 2,830,700 shares 2,830,700$62.4M6.9%+300,000Timeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,440,000 shares 2,440,000$46.1M5.1%newTimeline
AVBPARRIVENT BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,976,387 shares; 2024Q4: 2,059,387 shares; 2025Q1: 2,059,387 shares; 2025Q2: 1,946,054 shares; 2025Q3: 1,971,054 shares; 2025Q4: 1,971,054 shares; 2026Q1: 1,971,054 shares 1,971,054$45.5M5.03%0Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 4,572,222 shares; 2024Q4: 10,450,000 shares; 2025Q1: 10,700,000 shares; 2025Q2: 12,592,500 shares; 2025Q3: 9,067,500 shares; 2025Q4: 8,859,911 shares; 2026Q1: 8,859,911 shares 8,859,911$39.6M4.38%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 266,000 shares; 2025Q3: 360,000 shares; 2025Q4: 535,000 shares; 2026Q1: 425,000 shares 425,000$35.4M3.92%-110,000Timeline
MIRMMIRUM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 338,900 shares 338,900$31.3M3.46%newTimeline
BIOABIOAGE LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,598,000 shares; 2026Q1: 1,748,000 shares 1,748,000$30.6M3.38%+150,000Timeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,012,052 shares; 2024Q4: 1,993,052 shares; 2025Q1: 1,425,000 shares; 2025Q2: 1,030,000 shares; 2025Q3: 830,000 shares; 2025Q4: 750,000 shares; 2026Q1: 750,000 shares 750,000$29.8M3.3%0Timeline
KALVKALVISTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,370,000 shares; 2025Q1: 1,370,000 shares; 2025Q2: 1,273,333 shares; 2025Q3: 1,273,333 shares; 2025Q4: 1,273,333 shares; 2026Q1: 1,450,000 shares 1,450,000$29.2M3.23%+176,667Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 490,000 shares 490,000$28.5M3.15%newTimeline
TERNTERNS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 530,000 shares 530,000$27.9M3.09%newTimeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,425,000 shares; 2024Q4: 2,425,000 shares; 2025Q1: 2,425,000 shares; 2025Q2: 2,425,000 shares; 2025Q3: 2,624,000 shares; 2025Q4: 2,623,600 shares; 2026Q1: 3,166,600 shares 3,166,600$26.8M2.97%+543,000Timeline
PALIPALISADE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 9,567,898 shares; 2026Q1: 10,276,317 shares 10,276,317$18M1.99%+708,419Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 3,322,000 shares; 2025Q2: 3,672,000 shares; 2025Q3: 2,815,000 shares; 2025Q4: 2,815,000 shares; 2026Q1: 1,485,000 shares 1,485,000$17.7M1.96%-1,330,000Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 270,000 shares 270,000$17.3M1.91%newTimeline
AKTSAKTIS ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 960,847 shares 960,847$17.2M1.9%newTimeline
CNTXCONTEXT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 5,250,000 shares 5,250,000$13.8M1.52%newTimeline
DTILPRECISION BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,917,995 shares; 2026Q1: 2,236,732 shares 2,236,732$12.3M1.36%+318,737Timeline
DBVTDBV TECHNOLOGIES S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,018,021 shares; 2025Q3: 1,018,021 shares; 2025Q4: 574,200 shares; 2026Q1: 574,200 shares 574,200$12M1.33%0Timeline
UNCYUNICYCIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,000,000 shares; 2025Q3: 1,000,000 shares; 2025Q4: 1,000,000 shares; 2026Q1: 1,000,000 shares 1,000,000$6.58M0.73%0Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,043,110 shares; 2025Q4: 1,043,110 shares; 2026Q1: 719,000 shares 719,000$6.44M0.71%-324,110Timeline
LXEOLEXEO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,725,000 shares; 2026Q1: 1,100,000 shares 1,100,000$6.31M0.7%-625,000Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 620,470 shares; 2024Q4: 778,000 shares; 2025Q1: 769,815 shares; 2025Q2: 672,595 shares; 2025Q3: 722,595 shares; 2025Q4: 671,465 shares; 2026Q1: 165,000 shares 165,000$4.66M0.52%-506,465Timeline
CATXPERSPECTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,422,224 shares; 2024Q4: 2,304,752 shares; 2025Q1: 2,250,000 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 791,555 shares 791,555$3.3M0.37%newTimeline
EVMNEVOMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 500,000 shares; 2026Q1: 143,472 shares 143,472$3.3M0.37%-356,528Timeline
GOSSGOSSAMER BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 9,187,883 shares; 2024Q4: 18,350,000 shares; 2025Q1: 18,350,000 shares; 2025Q2: 18,350,000 shares; 2025Q3: 17,050,000 shares; 2025Q4: 13,915,371 shares; 2026Q1: 7,750,000 shares 7,750,000$2.55M0.28%-6,165,371Timeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
MIND MEDICINE MINDMED INCMIND MEDICINE MINDMED INC2,230,000$29.9Mshares
CGONCG ONCOLOGY INC600,000$24.9Mcall
CDTXCIDARA THERAPEUTICS INC100,000$22.1Mshares
RAPTRAPT THERAPEUTICS INC574,000$19.4Mshares
CRBPCORBUS PHARMACEUTICALS HLDGS955,000$7.77Mshares
PEPGPEPGEN INC700,000$4.56Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001839435-26-000003 base2026-05-15acceptance time not in the bulk data set